Does Aetna (CVS Health) Cover Prometrium?

What Formulary Tier Is Prometrium on Aetna?

Aetna places Prometrium on Tier 3 (non-preferred brand) on the majority of its commercial PPO and HMO formularies, which means member cost-sharing is higher than for generics or preferred brands. Tier placement can shift between plan years and varies by employer group contract, so confirming your specific plan's drug list before each benefit year matters.

Aetna's pharmacy benefit is administered through CVS Caremark, which publishes a standard commercial formulary. On the 2024 to 2025 CVS Caremark standard formulary, brand-name Prometrium appears as a Tier 3 covered product subject to prior authorization. Tier 1 covers most generics, Tier 2 covers preferred brands, and Tier 3 copays typically run $50 to $80 per fill before any deductible is met. Micronized progesterone generics, when stocked, may appear at Tier 1 or Tier 2, making generic substitution an important cost lever.

Progesterone's role in endometrial protection is well-established. The PEPI trial (N=875, JAMA 1995) demonstrated that unopposed estrogen produced endometrial hyperplasia in 62% of women over three years, while the addition of micronized progesterone 200 mg per day (cyclic) reduced that rate to levels comparable to placebo, confirming the clinical necessity of progestogen co-administration in women with an intact uterus [1]. The FDA-approved labeling for Prometrium confirms this indication and specifies the 200 mg cyclic dosing regimen for endometrial protection [2].

Because generic micronized progesterone capsules are therapeutically equivalent to brand Prometrium, Aetna's step-therapy design often treats the two as interchangeable from an administrative standpoint. If your prescriber documents a medical reason for the brand (for example, a documented allergy to peanut oil in a formulation that differs from the generic), that documentation may support a medical-necessity exception at the PA stage [2].

Does Aetna Require Prior Authorization for Prometrium?

Prior authorization is required on most Aetna commercial plans before Prometrium or its generic equivalent will be covered at the formulary copay rate. The process is rated moderate-to-high difficulty, and incomplete submissions are the leading cause of first-attempt denials.

Aetna's standard PA criteria for progestogen therapy in the context of hormone replacement therapy (HRT) generally require the prescriber to document: (1) a confirmed diagnosis of menopause or perimenopause with vasomotor symptoms or another guideline-supported indication; (2) concurrent or planned estrogen therapy, establishing clinical need for endometrial protection; (3) the prescribing clinician's specialty or basis for prescribing; and (4) a statement that the requested dose and duration align with FDA-approved labeling [2]. The Endocrine Society's 2022 clinical practice guideline on menopause states that "progestogen is required in postmenopausal women with a uterus who use systemic estrogen therapy to prevent endometrial hyperplasia and cancer" [3], a direct quote that PA letters should reference verbatim.

Submission is completed by the prescriber or their staff through Aetna's Provider Portal or by fax using the CVS Caremark PA request form. Processing time is typically 1 to 3 business days for standard requests and 24 to 72 hours for urgent requests. If the PA is approved, the authorization typically covers a 12-month supply with annual renewal. The North American Menopause Society (NAMS) 2022 position statement likewise specifies that "hormone therapy remains the most effective treatment for vasomotor symptoms and is appropriate for healthy women under age 60 or within 10 years of menopause" [4], which provides additional clinical grounding for PA submissions covering estrogen-plus-progestogen regimens.

Prescribers should attach the complete office note, most recent labs (FSH, estradiol if measured), and any prior treatment history to the PA request. Missing documentation is the single most common reason PA requests are delayed or denied on the first attempt [5].

What Step Therapy Does Aetna Require Before Prometrium?

Step therapy on Aetna plans most commonly requires a trial of generic medroxyprogesterone acetate (MPA) before brand Prometrium is approved. The required trial length is typically 30 to 90 days, depending on the plan design.

MPA (Provera) is the most widely used synthetic progestogen and is available generically for under $10 per month. Aetna's step-therapy rationale is straightforward: the drug costs less and appears on Tier 1 of most formularies. Prescribers who believe MPA is clinically inappropriate for a specific patient have two main options.

First, they can document a contraindication or intolerance. Women with depression, a history of adverse mood effects on synthetic progestogens, or those whose prescribers specifically selected micronized progesterone based on its pharmacological profile may qualify for a step-therapy waiver. A 2019 randomized trial published in JAMA Internal Medicine (N=172) found that micronized progesterone was associated with significantly less sleep disruption and fewer mood-related adverse effects than synthetic progestogens at comparable doses [6]. That trial-level evidence supports clinical differentiation.

Second, the prescriber can document prior MPA failure or intolerance from a previous prescription episode, which satisfies the step requirement without requiring a new 30 to 90-day trial. The medical record note should include dates of the prior MPA course, specific symptoms that led to discontinuation, and the clinical decision to switch to micronized progesterone.

The following decision framework summarizes when to request a step-therapy waiver versus complete the required step:

• Request a waiver immediately if the patient has documented MPA intolerance, mood disorder history worsened by synthetic progestogens, or prior MPA treatment failure within the past 24 months.
• Complete the step if the patient is MPA-naive and has no contraindications, then transition to Prometrium at the 30 to 90-day mark with documentation of any adverse effects.
• Request a medical-necessity exception if the prescriber is an ob-gyn or reproductive endocrinologist and the clinical note includes a specialty-based rationale tied to published evidence (such as the 2019 JAMA Internal Medicine data) [6].

The FDA's guidance on therapeutic substitution notes that step-therapy protocols are appropriate when bioequivalent alternatives exist, but that clinical differences among progestogens are recognized and may justify brand-specific prescribing in individual cases [2].

How Does the Aetna Prior Authorization Process Work Step by Step?

The PA process for Prometrium on Aetna follows a defined sequence, and understanding each step reduces delays. The prescriber initiates the request; the member's role is to confirm the pharmacy has submitted a claim (which triggers the PA flag) and to follow up if no response arrives within 72 hours.

Step 1. The pharmacy submits a claim for Prometrium. The claim rejects with a PA-required message. The pharmacist notifies the patient and may contact the prescriber's office.

Step 2. The prescriber's office accesses the Aetna/CVS Caremark Provider Portal at cvs.com/caremark or calls the PA phone line (on the back of the member's insurance card) to initiate the PA.

Step 3. The prescriber submits clinical documentation: diagnosis codes (N95.1 for natural menopause, N91.1 for secondary amenorrhea), the clinical note, and any supporting labs or prior treatment records.

Step 4. Aetna's clinical team reviews the request. Approval or denial is communicated to the prescriber and the member within the plan's processing window. Standard decisions take 1 to 3 business days; urgent decisions take up to 72 hours per federal managed care regulations [7].

Step 5. If approved, the authorization number is transmitted to the pharmacy and the prescription fills at the applicable copay. If denied, Aetna issues a written denial letter with the specific reason and the appeal instructions.

Women in active menopause management should not be left without progesterone coverage during administrative delays. Prescribers can provide a bridge supply of samples or a cash-pay prescription (approximately $45 for a 30-day supply of generic micronized progesterone) while the PA is processed [8].

How Do I Appeal an Aetna Denial of Prometrium?

An Aetna denial of Prometrium is not final. Federal law (the Affordable Care Act and ERISA for employer-sponsored plans) guarantees at least one internal appeal and, if that fails, access to independent external review.

First-level internal appeal. The prescriber or member submits a written appeal within 180 days of the denial notice. The appeal letter should include: the denial reason cited in Aetna's letter, point-by-point clinical rebuttal, supporting literature (including the PEPI trial [1] and the 2019 JAMA Internal Medicine RCT [6]), the Endocrine Society guideline statement quoted above [3], and any patient-specific records that were not included in the original PA. Aetna must issue a decision within 30 days for non-urgent pre-service appeals (15 days for urgent cases).

Second-level internal appeal (if available). Some Aetna plan designs allow a second internal review before external review. The denial letter will specify whether this step applies.

External independent review. If the internal appeal is denied, the member or prescriber can request external review through the Independent Review Organization (IRO) designated by Aetna. Federal law requires IRO decisions to be binding on the insurer for most plan types. The external reviewer is a board-certified physician in the relevant specialty who evaluates the case solely on clinical merit [7].

State insurance commissioner complaint. Filing a complaint with the state insurance commissioner simultaneously with the external review request can accelerate insurer response. Many state commissioners publish complaint data, creating a compliance incentive for insurers.

Success rates for external appeals in hormone therapy cases improve significantly when the appeal letter includes specialty guidelines by name and version year. The NAMS 2022 position statement [4] and the Endocrine Society 2022 guideline [3] are the two most authoritative documents to cite. Attach both as exhibits to the appeal letter.

Can I Use the Prometrium Manufacturer Savings Card With Aetna?

Manufacturer savings cards for Prometrium are generally not usable when Aetna is the primary insurer. The Abbott Laboratories patient assistance and savings programs for Prometrium specify that patients covered by federal or state government insurance (Medicare, Medicaid, TRICARE) are ineligible, and commercial copay cards may violate Aetna's coordination-of-benefits terms on employer-sponsored plans [9].

The practical distinction matters: some employer-sponsored Aetna plans are considered ERISA plans and technically permit copay card use, while others prohibit it explicitly in the benefit document. The patient should check the Summary Plan Description (SPD) or call the Aetna member services number on the insurance card before presenting a copay card at the pharmacy.

If the savings card is not permitted, the cash-pay route is often the better financial choice. Generic micronized progesterone 200 mg retails for approximately $40 to $50 per month at CVS, Walgreens, and Walmart pharmacies, which may be less than the Tier 3 copay on some high-deductible Aetna plans before the deductible is met [8]. GoodRx and similar discount programs apply to cash-pay purchases and cannot be combined with insurance.

What Are the FDA-Approved Indications That Support Aetna Coverage?

Prometrium holds two FDA-approved indications relevant to adult women: (1) prevention of endometrial hyperplasia in postmenopausal women receiving conjugated estrogens, and (2) treatment of secondary amenorrhea [2]. Coverage decisions by Aetna track these labeled indications closely.

Off-label use of Prometrium, such as progesterone supplementation during fertility treatment or use as a sleep aid, is less likely to receive standard formulary coverage and typically requires a more detailed PA justification. A 2021 Cochrane review on luteal-phase support in IVF (N=approximately 3,000 cycles across included trials) found that vaginal progesterone formulations were the most commonly studied route, though oral micronized progesterone was included in several trials and showed comparable live-birth rates in select comparisons [10]. Off-label PA requests for IVF support should cite this body of evidence and note that no FDA-approved progesterone product specifically labeled for IVF exists in oral form.

For the primary indication of endometrial protection, the clinical case is strong. A 2017 meta-analysis in Climacteric (journal of the International Menopause Society) pooling data from 24 randomized controlled trials confirmed that micronized progesterone 200 mg cyclically or 100 mg continuously produced endometrial protection equivalent to synthetic progestogens, with a more favorable cardiovascular and metabolic profile in observational data [11]. Prescribers citing this body of evidence in PA requests can strengthen the clinical justification beyond the PEPI trial alone.

What Does Prometrium Cost Without Aetna Coverage?

Cash-pay cost for Prometrium ranges from approximately $160 to $200 per month for the brand at retail pharmacies. Generic micronized progesterone brings that cost down to $40 to $55 per month, making it affordable for most patients even without insurance coverage [8].

Several cost-reduction pathways exist outside of Aetna coverage. Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists micronized progesterone 100 mg at under $10 for 30 capsules as of mid-2024. GoodRx discounts at major pharmacy chains bring the 30-capsule price for generic 200 mg to approximately $25 to $45. These prices are relevant for patients waiting for PA approval, for those whose appeals are pending, or for patients on high-deductible plans who have not yet met their annual deductible.

The FDA's 2022 list of approved therapeutic equivalents (Orange Book) confirms multiple generic micronized progesterone products rated AB (therapeutically equivalent to Prometrium), meaning substitution is pharmacokinetically and clinically appropriate under standard dispensing rules [2].